(Reuters) – Sanofi and Regeneron Pharmaceuticals said on Thursday they would continue a large clinical outcomes study with their injectable cholesterol-lowering drug Praluent. There had been an option for the trial to be stopped early if it showed overwhelming efficacy at the interim stage but an independent data monitoring committee recommended it should continue. The treatment belongs to a new class of medicines targeting the PCSK9 protein that maintains LDL cholesterol in the bloodstream.
Read the original post:
No early win for Sanofi, Regeneron cholesterol drug in study
